

# Vasiliki Liakouli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5933344/publications.pdf>

Version: 2024-02-01

73  
papers

3,315  
citations

109264

35  
h-index

155592

55  
g-index

73  
all docs

73  
docs citations

73  
times ranked

4400  
citing authors

#	ARTICLE	IF	CITATIONS
1	Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?. <i>Autoimmunity Reviews</i> , 2011, 10, 595-598.	2.5	168
2	The Role of IL-1 $\beta$ in the Bone Loss during Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	146
3	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , 2013, 15, R172.	1.6	143
4	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , 2016, 14, 194.	2.3	130
5	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>Trends in Rheumatology</i> , 2017, 23, 107.	2.5	107
6	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
7	Methotrexate: an old new drug in autoimmune disease. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1519-1530.	1.3	100
8	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 $\beta$ via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. <i>Clinical and Experimental Immunology</i> , 2015, 182, 35-44.	1.1	100
9	The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 598-605.	0.5	97
10	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002901.	3.9	94
11	Angiogenic cytokines and growth factors in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2011, 10, 590-594.	2.5	88
12	Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. <i>Clinical Rheumatology</i> , 2014, 33, 49-55.	1.0	84
13	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- $\beta$ 2 and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. <i>Journal of Rheumatology</i> , 2015, 42, 1808-1816.	1.0	82
14	Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1845-1851.	0.5	77
15	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , 2017, 37, 853-863.	1.5	76
16	Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). <i>European Journal of Radiology</i> , 2013, 82, e268-e273.	1.2	66
17	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , 2017, 16, 16-21.	2.5	65
18	Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. <i>Arthritis and Rheumatism</i> , 2006, 54, 3022-3033.	6.7	64

#	ARTICLE	IF	CITATIONS
19	Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. Current and Emerging Paradigms. <i>Clinical Therapeutics</i> , 2014, 36, 427-435.	1.1	62
20	Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. <i>Angiogenesis</i> , 2013, 16, 595-607.	3.7	61
21	Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. <i>Clinical and Experimental Immunology</i> , 2013, 173, 195-206.	1.1	59
22	Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. <i>Clinical Rheumatology</i> , 2017, 36, 2839-2845.	1.0	53
23	Cellular players in angiogenesis during the course of systemic sclerosis. <i>Autoimmunity Reviews</i> , 2011, 10, 641-646.	2.5	52
24	Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. <i>Autoimmunity Reviews</i> , 2013, 12, 709-716.	2.5	51
25	Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. <i>Arthritis Research and Therapy</i> , 2014, 16, 442.	1.6	49
26	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. <i>Autoimmunity Reviews</i> , 2015, 14, 429-437.	2.5	46
27	IL-1 $\beta$ at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 849-855.	1.3	46
28	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. <i>Journal of Rheumatology</i> , 2016, 43, 1340-1349.	1.0	45
29	Surface Expression of Fractalkine Receptor (CX3CR1) on CD4+/CD28 T Cells in RA Patients and Correlation with Atherosclerotic Damage. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 32-41.	1.8	43
30	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e7896.	0.4	42
31	Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0181203.	1.1	42
32	A genetic variation located in the promoter region of the <i>UPAR</i> ( <i>CD87</i> ) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 247-256.	6.7	41
33	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. <i>PLoS ONE</i> , 2017, 12, e0170108.	1.1	41
34	H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. <i>Clinical and Experimental Immunology</i> , 2016, 186, 30-38.	1.1	40
35	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational CIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	1.6	40
36	Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population. <i>Journal of Rheumatology</i> , 2010, 37, 1852-1857.	1.0	39

#	ARTICLE	IF	CITATIONS
37	H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. <i>Clinical and Experimental Immunology</i> , 2018, 191, 220-228.	1.1	38
38	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	1.6	38
39	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
40	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1041-1047.	1.3	36
41	The $\gamma$ 670G>A polymorphism in the <i>FAS</i> gene promoter region influences the susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 584-590.	0.5	34
42	Safety and efficacy of intra-articular anti-tumor necrosis factor $\pm$ agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 252-266.	1.0	32
43	Association between a stromal cell-derived factor 1 ( <i>SDF-1/CXCL12</i> ) gene polymorphism and microvascular disease in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 408-411.	0.5	29
44	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 223.	1.6	29
45	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , 2015, 9, 123.	0.4	28
46	Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. <i>Medicine (United States)</i> , 2017, 96, 107-113.	0.4	27
47	Scleroderma fibroblasts suppress angiogenesis via TGF- $\beta$ 2/caveolin-1 dependent secretion of pigment epithelium-derived factor. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 431-440.	0.5	26
48	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2014, 7, 13.	3.4	24
49	Macitentan inhibits the transforming growth factor- $\beta$ 2 profibrotic action, blocking the signaling mediated by the ETR/ $\text{T}^2$ RI complex in systemic sclerosis dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2015, 17, 247.	1.6	22
50	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. <i>Clinical Rheumatology</i> , 2017, 36, 251-260.	1.0	22
51	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. <i>Modern Rheumatology</i> , 2018, 28, 922-932.	0.9	21
52	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	20
53	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. <i>Rheumatology International</i> , 2020, 40, 107-113.	1.5	20
54	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , 2015, 17, 832-849.	0.3	19

#	ARTICLE	IF	CITATIONS
55	Variations of neuronal nitric oxide synthase in systemic sclerosis skin. <i>Arthritis and Rheumatism</i> , 2006, 54, 202-213.	6.7	18
56	Jejunioileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 441-452.	1.3	18
57	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. <i>Scientific Reports</i> , 2019, 9, 7144.	1.6	18
58	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2020, 22, 127.	1.6	18
59	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1247-1260.	0.9	15
60	Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. <i>International Journal of Oncology</i> , 2018, 54, 537-549.	1.4	12
61	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. <i>Scientific Reports</i> , 2019, 9, 4589.	1.6	12
62	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. <i>PLoS ONE</i> , 2019, 14, e0211142.	1.1	11
63	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). <i>Molecular Medicine Reports</i> , 2019, 20, 1488-1498.	1.1	10
64	The Vessels Contribute to Fibrosis in Systemic Sclerosis. <i>Israel Medical Association Journal</i> , 2019, 21, 471-474.	0.1	10
65	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. <i>Archives of Medical Science</i> , 2016, 4, 828-843.	0.4	7
66	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- $\beta$ 2 and IL-6. <i>Pharmaceuticals</i> , 2022, 15, 622.	1.7	7
67	Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 931-942.	1.3	5
68	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 277-291.	0.6	3
69	Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e53-e53.	0.5	3
70	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 995-1002.	0.4	2
71	Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	2
72	Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2348-2348.	2.9	1

#	ARTICLE	IF	CITATIONS
73	Potential of stem cells in the treatment of rheumatic disease. International Journal of Clinical Rheumatology, 2014, 9, 183-195.	0.3	0